The AURKA inhibitor alisertib has demonstrated some clinical efficacy against SCLC both alone and in combination with paclitaxel (Table 1), and MYC expression was found to be a biomarker of treatment efficacy [71,72]. Here, MYC is linked to small cell lung carcinoma.